Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroendocrine
Biotech
Sanofi $110M radioligand therapy hits main goal in ph. 2 trial
Sanofi’s bet on a radioligand therapy seems to be paying off after the neuroendocrine tumor treatment hit the key endpoints of a phase 2 study.
James Waldron
Oct 8, 2025 6:25am
Sanofi pays $110M upfront for late-stage radioligand therapy
Sep 12, 2024 4:54am
Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win
Mar 13, 2024 9:16am
Carl June's latest CAR-T work taps llamas for GI cancers
Mar 29, 2022 9:00am
Chi-Med's surufatinib fends off pancreatic tumors in phase 3
Sep 18, 2020 6:05pm
Chi-Med stops pivotal pancreatic cancer trial upon early success
Jan 21, 2020 8:30am
